January 2025 – LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading Pharmaceutical technology company, is proud to announces ...

PopVax awarded $2M for its patch-delivered mRNA influenza vaccine in collaboration with LTS Lohmann as part of BARDA’s Patch Forward Prize.

ANDERNACH, GERMANY - Newsaktuell - 14 January 2025 - LTS LOHMANN Therapie-Systeme AG (LTS), a leading <a target=_blank href= ...

Simcere Pharmaceutical said on Monday its unit had granted U.S. drugmaker AbbVie the option to license its new blood cancer ...

Learn more about Christopher Missling, PhD, on LinkedIn and explore the innovative work of Anavex Life Sciences at their website. In the relentless pursuit of solutions for neurodegenerative diseases ...

ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...

AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically cleared for folate receptor-alpha (FRα) positive, platinum-resistant ...

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

PopVax, an Indian biotechnology company, won $2 million from BARDA for its innovative mRNA influenza vaccine. Developed in partnership with Germany's LTS Lohmann, the vaccine utilizes a unique ...

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...

A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, management will be available for one-on-one meetings with ...